Medications for Metastatic Nonsmall Cell Lung Cancer

3 results
  • tabrecta - capmatinib tablet, film coated

    (Capmatinib)
    Novartis Pharmaceuticals Corporation
    Tabrecta treats adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a MET exon 14 skipping mutation detected by an FDA-approved test.
  • vizimpro - dacomitinib tablet, film coated

    (Dacomitinib)
    Pfizer Laboratories Div Pfizer Inc
    VIZIMPRO is indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.